Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
January 29 2024 - 7:30AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the
recipients of its sixth annual Communications Grant Program,
intended to support increased capacity in communications, awareness
building and community engagement.
Five grants in the amount of $20,000 each were
awarded this year to patient advocacy organizations focused on the
hypertrophic cardiomyopathy (HCM), heart failure and amyotrophic
lateral sclerosis (ALS) communities. The grants will support
projects to increase access to resources, grow organizational reach
and launch educational programs.
“Our unwavering commitment is first and foremost
to patients which we demonstrate every day by advancing our science
while also supporting patient advocacy organizations with shared
values and missions,” said Mary Pomerantz, Cytokinetics’ Senior
Director of Patient Advocacy and Engagement. “We are inspired by
this year’s recipients who have articulated creative, impactful and
compelling strategies to address the distinctive needs of the
patient communities they serve.”
The recipients of the 2024 Cytokinetics
Communications Grants include:
ALS Therapy Development
Institute: The ALS Therapy Development Institute (ALS TDI)
is a non-profit drug discovery lab focused solely on ALS with the
goal of pursuing every avenue towards slowing, stopping and ending
ALS. With the grant, ALS TDI will launch the ALS Trial Navigator, a
unique online platform that guides patients as they learn more
about finding and participating in clinical trials for experimental
ALS treatments. The ALS Trial Navigator will provide tools
including a detailed questionnaire designed to help people with ALS
and their caregivers learn about what trials may meet their needs
and a filterable, searchable list of recruiting clinical studies
around the world.
Cardiomyopathy UK:
Cardiomyopathy UK is a specialist national charity for people
affected by cardiomyopathy with a vision that everyone affected by
cardiomyopathy should live a long and fulfilling life.
Cardiomyopathy UK will use the grant to expand Reaching Further, a
project aimed at educating those not diagnosed with cardiomyopathy
about the symptoms and warning signs. The grant will allow
Cardiomyopathy UK to create 15 additional case study stories and
refine and optimize the organization’s website.
Global Heart Hub: Global Heart
Hub (GHH) is a global non-profit organization established to
provide a voice for those living with or affected by cardiovascular
disease and serves as an alliance of over 100 heart patients
organizations, with affiliates forming Patient Councils focused on
specific cardiovascular conditions. The GHH Cardiomyopathy Patient
Council currently has 22 patient organization affiliates across 13
countries. The grant will help fund GHH’s Key Messages Project
which will create foundational cardiomyopathy messages to be used
by patient organizations to have consistent and powerful messaging
when communicating the scale, scope and impact of cardiomyopathy to
patients, caregivers, healthcare professionals and
policymakers.
HeartBrothers Foundation: The
HeartBrothers Foundation is a non-profit organization dedicated to
helping heart failure patients and their families navigate the
complex journey of heart failure, mechanical circulatory support
and heart transplantation. HeartBrothers will utilize this grant to
expand outreach efforts, foster digital and in-person partnerships
with heart failure hospitals nationwide and increase overall
awareness and information about patient resources.
WomenHeart: The
National Coalition for Women with Heart Disease:
WomenHeart is a patient-centered organization that strives to
advance women’s heart health through patient support, community
education and advocacy. WomenHeart will use this grant to help fund
the organization’s 25th anniversary campaign. The campaign will
raise awareness of women’s heart health by spotlighting the
unwavering commitment of WomenHeart Champions and sharing their
powerful stories to engage and inspire other women to learn more,
take action to improve their heart health and become WomenHeart
Champions.
About the Cytokinetics Communications
Grant Program
For the past six years, the Cytokinetics
Communications Grant Program has supported patient advocacy
organizations to help expand their reach, awareness and community
engagement by providing resources for new or crucial communication
or outreach initiatives that would otherwise be challenging to
implement. Cytokinetics has no oversight, involvement or management
of the actual projects, programs or outputs. The goal of the
Communications Grant Program is to assist patient advocacy
organizations by increasing resources in order to better support
patient communities and bring increased disease awareness in the
communities they serve. The call for proposals for the 2025
Communications Grant Program will be announced during Fall
2024.
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators and
next-in-class muscle inhibitors as potential treatments for
debilitating diseases in which cardiac muscle performance is
compromised. As a leader in muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to impact myocardial muscle
function and contractility. Cytokinetics is preparing for
regulatory interactions for aficamten, its next-in-class cardiac
myosin inhibitor, following positive results from SEQUOIA-HCM, the
pivotal Phase 3 clinical trial in obstructive hypertrophic
cardiomyopathy. Aficamten is also currently being evaluated in two
ongoing Phase 3 clinical trials: MAPLE-HCM, evaluating aficamten as
monotherapy compared to metoprolol as monotherapy in patients with
obstructive HCM and ACACIA-HCM, evaluating aficamten in patients
with non-obstructive HCM. Cytokinetics is also developing omecamtiv
mecarbil, a cardiac muscle activator, in patients with heart
failure. Additionally, Cytokinetics is developing CK-136, a cardiac
troponin activator for the potential treatment HFrEF and other
types of heart failure, such as right ventricular failure,
resulting from impaired cardiac contractility, and CK-586, a
cardiac myosin inhibitor with a mechanism of action distinct from
aficamten for the potential treatment of HFpEF.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act’s Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics’ and its partners’
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management’s current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics’ business outlines in Cytokinetics’
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics’ actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in
this press release speak only as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped
logo are registered trademarks of Cytokinetics in the U.S. and
certain other countries.
Contact:Cytokinetics Diane WeiserSenior Vice President,
Corporate Communications, Investor Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2024 to May 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From May 2023 to May 2024